Drug profile · INN
darifenacin hydrobromide
EMSELEX
- US status
- approved
- Patents linked
- 1
- News articles
- 0
Quick answer
darifenacin hydrobromide (EMSELEX) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN darifenacin hydrobromide
Brand EMSELEX
Route ORAL
Formulation TABLET, EXTENDED RELEASE
ATC code G04BD10
Related patents
Search patents →Frequently asked questions
What is darifenacin hydrobromide?
darifenacin hydrobromide (EMSELEX) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for darifenacin hydrobromide?
EMSELEX is a marketed brand name for darifenacin hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of darifenacin hydrobromide?
darifenacin hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.